164 related articles for article (PubMed ID: 25592467)
21. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.
Chen M; Pratt CP; Zeeman ME; Schultz N; Taylor BS; O'Neill A; Castillo-Martin M; Nowak DG; Naguib A; Grace DM; Murn J; Navin N; Atwal GS; Sander C; Gerald WL; Cordon-Cardo C; Newton AC; Carver BS; Trotman LC
Cancer Cell; 2011 Aug; 20(2):173-86. PubMed ID: 21840483
[TBL] [Abstract][Full Text] [Related]
22. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
23. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD
Am J Pathol; 2011 Jul; 179(1):502-12. PubMed ID: 21703427
[TBL] [Abstract][Full Text] [Related]
24. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
[TBL] [Abstract][Full Text] [Related]
25. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
[TBL] [Abstract][Full Text] [Related]
26. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
27. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
[TBL] [Abstract][Full Text] [Related]
28. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
29. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
30. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
31. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
32. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
33. Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer.
Alioui A; Dufour J; Leoni V; Loregger A; Moeton M; Iuliano L; Zerbinati C; Septier A; Val P; Fouache A; Russo V; Volle DH; Lobaccaro JA; Zelcer N; Baron S
Nat Commun; 2017 Sep; 8(1):445. PubMed ID: 28874658
[TBL] [Abstract][Full Text] [Related]
34. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.
Chen M; Zhang J; Sampieri K; Clohessy JG; Mendez L; Gonzalez-Billalabeitia E; Liu XS; Lee YR; Fung J; Katon JM; Menon AV; Webster KA; Ng C; Palumbieri MD; Diolombi MS; Breitkopf SB; Teruya-Feldstein J; Signoretti S; Bronson RT; Asara JM; Castillo-Martin M; Cordon-Cardo C; Pandolfi PP
Nat Genet; 2018 Feb; 50(2):206-218. PubMed ID: 29335545
[TBL] [Abstract][Full Text] [Related]
35. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis.
Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY
Nature; 2013 Jan; 493(7431):236-40. PubMed ID: 23201680
[TBL] [Abstract][Full Text] [Related]
36. A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.
de la Rosa J; Weber J; Friedrich MJ; Li Y; Rad L; Ponstingl H; Liang Q; de Quirós SB; Noorani I; Metzakopian E; Strong A; Li MA; Astudillo A; Fernández-García MT; Fernández-García MS; Hoffman GJ; Fuente R; Vassiliou GS; Rad R; López-Otín C; Bradley A; Cadiñanos J
Nat Genet; 2017 May; 49(5):730-741. PubMed ID: 28319090
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
Wang S; Gao J; Lei Q; Rozengurt N; Pritchard C; Jiao J; Thomas GV; Li G; Roy-Burman P; Nelson PS; Liu X; Wu H
Cancer Cell; 2003 Sep; 4(3):209-21. PubMed ID: 14522255
[TBL] [Abstract][Full Text] [Related]
38. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Møller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A;
Cancer Res; 2010 Feb; 70(3):979-87. PubMed ID: 20103652
[TBL] [Abstract][Full Text] [Related]
39. β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.
Francis JC; Thomsen MK; Taketo MM; Swain A
PLoS Genet; 2013; 9(1):e1003180. PubMed ID: 23300485
[TBL] [Abstract][Full Text] [Related]
40. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]